SPY310.52+2.16 0.70%
DIA257.31-0.56 -0.22%
IXIC10,154.63+95.86 0.95%

Goldman Sachs Initiates Coverage On Phathom Pharmaceuticals with Neutral Rating, Announces $32 Price Target

Goldman Sachs initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral rating and a $32 price target.

Benzinga · -

Goldman Sachs initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral rating and a $32 price target.